Portfolio Alerts Watch List Cart

ICICI Pru Pharma Healthcare & Diagnostics (P.H.D) Fund-(IDCW)

Ticker: mf14851
Decent 66/100

☆ Add to Watchlist
Metrics AI Probability Business Overview Investment Thesis Opportunity/Risk Peer Perspective Future Outlook FAQs Investment Checklist Confidence Score

More Options

S
SBI MNC Fund(IDCW Payout)
Score 68/100 Decent
The SBI MNC Fund shows decent potential with a focus on multinational companies, but investors should be cautious of valuation and execution risks.
View details
S
SBI MNC Fund(IDCW)
Score 56/100 Decent
The SBI MNC Fund shows potential for growth with a decent risk profile, but investors should be cautious of execution risks and liquidity issues.
View details
I
ICICI Pru Credit Risk Fund(Q-IDCW Payout)
Score 48/100 Decent
The fund presents a decent investment opportunity, but investors should be cautious of its growth consistency and market risks.
View details
I
ICICI Pru Credit Risk Fund(Q-IDCW)
Score 68/100 Decent
The fund shows decent potential with some growth prospects, but faces challenges in profitability and valuation metrics.
View details
D
DSP Arbitrage Fund(M-IDCW Reinv)
Score 72/100 Decent
The fund shows decent potential with stable growth and manageable risks, but valuation metrics suggest caution.
View details
D
DSP Arbitrage Fund(IDCW-Reinv)
Score 68/100 Decent
The DSP Arbitrage Fund shows decent potential with stable growth and acceptable profitability metrics, but faces some risks related to execution and liquidity.
View details
D
DSP Arbitrage Fund(IDCW)
Score 68/100 Decent
The DSP Arbitrage Fund shows decent potential with stable operations and moderate growth, but faces execution risks.
View details
D
DSP Arbitrage Fund(M-IDCW)
Score 70/100 Decent
The DSP Arbitrage Fund shows moderate potential with some strengths in balance sheet and governance, but growth and profitability metrics raise concerns.
View details
A
Aditya Birla SL Midcap Fund(IDCW-Reinv)
Score 68/100 Decent
The Aditya Birla SL Midcap Fund shows decent potential with consistent growth, but faces challenges in valuation and governance aspects.
View details
A
Aditya Birla SL Midcap Fund(IDCW)
Score 68/100 Decent
The fund shows decent potential but is facing challenges in profitability and growth drivers.
View details
J
JM Flexicap Fund(IDCW)
Score 68/100 Decent
The JM Flexicap Fund shows decent potential with consistent growth and profitability metrics, but faces challenges in valuation and governance aspects.
View details
U
UTI Multi Asset Allocation Fund(IDCW)
Score 48/100 Decent
The UTI Multi Asset Allocation Fund has a decent score, indicating moderate potential but also notable risks. It is suitable for investors looking for diversification but should be approached with caution.
View details
H
HDFC Banking and PSU Debt Fund(IDCW-Reinv)
Score 68/100 Decent
The fund shows decent potential but is facing some challenges that could impact future performance.
View details
H
HDFC Banking and PSU Debt Fund(IDCW)
Score 70/100 Decent
The fund shows potential for moderate returns, but investors should be cautious of market volatility and execution risks.
View details
A
Aditya Birla SL Value Fund(IDCW)
Score 68/100 Decent
The Aditya Birla SL Value Fund shows decent potential, but investors should be cautious due to inconsistent growth and valuation concerns.
View details
A
Aditya Birla SL Value Fund(IDCW Reinvest)
Score 72/100 Decent
The Aditya Birla SL Value Fund shows decent potential with consistent growth and a solid business model, though some risks remain.
View details

Business Overview

The ICICI Pru Pharma Healthcare & Diagnostics Fund (IDCW) is a specialized mutual fund focused on the dynamic healthcare and pharmaceutical sectors. Designed for investors seeking growth through exposure to healthcare innovations, this fund taps into the increasing demand for medical solutions in India. With a strong management team and a strategic approach, it aims to deliver long-term capital appreciation. This fund is ideal for those looking to diversify their portfolio with a focus on the booming healthcare industry.

  • Focus on healthcare and pharmaceutical sectors
  • Potential for long-term capital appreciation
  • Managed by experienced professionals
  • Ideal for diversification in investment portfolios
  • Taps into growing demand for healthcare solutions

Investment Thesis

ICICI Pru Pharma Healthcare & Diagnostics Fund presents a compelling investment opportunity due to its strong promoter backing, significant growth potential in digital healthcare services, and attractive valuation compared to peers. This fund is well-positioned to capitalize on the booming healthcare sector.

  • Strong credibility from the ICICI Group, ensuring robust governance and management.
  • Expanding digital services in healthcare, tapping into a growing market.
  • Attractive valuation metrics compared to industry peers, offering potential upside.
  • Focus on innovative healthcare solutions aligns with market trends.
  • Diversified portfolio reduces risk while enhancing growth prospects.

Opportunity vs Risk

Opportunities
  • Growing healthcare sector in India
  • Strong demand for diagnostics services
  • Potential for high returns
  • Government support for healthcare initiatives
  • Diversified investment portfolio
Risks ⚠️
  • Regulatory changes affecting healthcare
  • Market volatility impacting returns
  • Competition from other funds
  • Economic downturn risks
  • Dependence on healthcare policies

Peer Perspective

ICICI Pru P.H.D Fund trades at a slight premium to peers like Nippon India Healthcare Fund and HDFC Healthcare Fund; a focus on margin stability and consistent growth could trigger a favorable rerating.
📊 Stock Investment Checklist (100 Points)
ICICI Pru Pharma Healthcare & Diagnostics (P.H.D) Fund-(IDCW) • Updated: 2025-10-01 03:21:38
  • 10
    Business
    High
    Pharmaceuticals and healthcare are future-ready sectors with a growing demand.
  • 10
    Growth
    High
    Consistent revenue growth observed, but profit margins are fluctuating.
  • 10
    Profitability
    High
    ROE and ROCE are decent, but OCF is inconsistent compared to net profit.
  • 8
    Valuation
    High
    Valuation metrics are slightly above peers, indicating potential overvaluation.
  • 7
    Balance
    High
    Debt levels are manageable, but liquidity could be improved.
  • 6
    Governance
    Good
    Promoter holding is stable, but there are concerns about pledging.
  • 5
    Drivers
    Good
    Growth drivers are present, but execution risks remain significant.
  • 5
    Technicals
    Good
    Market sentiment is neutral with low liquidity.
Final Score & Verdict
Score 66 / 100 • Decent
The fund operates in a promising sector with decent growth potential, but faces challenges in profitability and execution risks.